In vitro (activated p53-dependent transcription); in vivo (antitumor effect in a MOLM13 mouse xenograft model and eight TCL PDX models, activated anti-tumor immune response in Colon26 allografts, and synergistic effect in MCF-7 and ZR-75-1 mouse xenograft models); clinical trial (NCT02264613). Here, TP53 is linked to neoplasm.